PubMed · 2013 · 68 citations · 14 references
MedicinePharmacologyPharmacotherapyEpidemiologyObesity PreventionPathophysiologyInsulin ResistanceMetabolic SyndromeObesity EpidemiologyObesity ManagementObesity PharmacotherapyWeight ManagementLow Body Mass IndexObesity IncidenceObesity TreatmentObesity-related Mortality
In the U.S., obesity is prevalent in epidemic proportions, and rates continue to rise. Current data indicate that the combined prevalence of overweight and obese adults in the U.S. is 69.2%.1 The prevalence of obesity alone accounts for 35.7% of adults in the U.S., with men and women equally affected.2 In the U.S., approximately 18.4% of adolescents 12 to 19 years of age are obese.1 Obesity is defined as a body mass index (BMI) of 30 kg/m2 or more. Over-weight is defined as a BMI of 25 to 29.9 kg/m2.3 Obesity is a significant risk factor contributing to the development of hypertension, type-2 diabetes mellitus, hyperlipidemia, coronary heart disease, stroke, metabolic syndrome, sleep apnea, osteoarthritis, gallbladder disease, fatty liver disease, pregnancy complications, and some cancers.4 Obesity is also a major cause of preventable death in the U.S.5 Increased health care costs are also associated with obesity and its related comorbidities. Obesity-related health costs in the U.S. are estimated at $147 billion annually.6 The exact cause of obesity is unknown; the condition develops from multiple genetic, behavioral, physiological, social, and metabolic factors.7 Goals of treatment include a reduction in baseline body weight, dietary changes, increased physical activity, and behavioral modifications to address the complexity of the condition.7 In clinically severe obesity, defined as a BMI of 40 or greater, or a BMI of 35 or greater with comorbid conditions, weight-loss surgery may be indicated.7 Ultimately, a reduction in mortality rates and an increased quality of life are the aims of treatment. To address the growing prevalence and the related comorbidities associated with obesity, researchers have explored alternative therapies to behavior, diet, exercise, and surgery to promote weight loss, including pharmacological treatments.7 Earlier and current weight-loss medications have been designed to reduce appetite, increase satiety, and decrease the absorption of nutrients. Thyroid hormone, amphetamines, diethylpropion (e.g., Tenuate, formerly Sanofi Aventis), fenfluramine (Pondimin, American Home Products/ Wyeth), dexfenfluramine (e.g., Redux, Wyeth), orlistat (Alli, GlaxoSmithKline; Xenical, Roche/Genentech), sibutramine (Meridia, Abbott), rimonabant (Acomplia, Sanofi), and phenylpropanolamine (now available only for dogs) have been investigated and used in the treatment of obesity. However, many of these medications have been withdrawn from the market because of their adverse-risk profiles and safety concerns.8 On June 27, 2012, the FDA approved lorcaserin (Belviq, Arena/Eisai) for the treatment of obesity. Formerly known as Lorqess, this small-molecule agonist of the serotonin 2C (5-HT2C) receptor is designed to promote weight loss in obese and overweight patients as an adjunct to a reduced-calorie diet and increased physical activity.9 The selectivity of lorcaserin at the 5-HT2C receptors is an advantage to both its efficacy and safety by exerting its appetite-suppressing effects while avoiding cardiovascular effects that occurred in previous nonselective serotonergic weight-loss medications.8 Three phase 3 clinical trials have demonstrated safety and efficacy for lorcaserin (see pages 526–529).9–11
14
European Guidelines for Obesity Management in Adults
Volkan Yumuk, Constantine Tsigos, Martin Fried et al. · Obesity Facts · 2015 · 3.4K citations · Full text